Jeffrey B. Kindler, J.D.
Mr. Kindler has served as the Executive Chairman of vTv since 2015. Mr. Kindler is also the CEO of Centrexion, a privately held clinical stage biopharmaceutical company; a Venture Partner at Lux Capital, a leading venture capital firm; and a managing director at Starboard Capital Partners, a Connecticut-based private equity firm. He also serves on the boards of AgaMatrix Inc., a developer and manufacturer of diabetes products; Intrexon Corporation, a synthetic biology company; PPD, a global contract drug discovery and development research organization; a number of other privately held companies.
Mr. Kindler was formerly the Chairman and Chief Executive Officer of Pfizer, Inc. which he joined in January 2002 and from which he retired in December 2010. He joined Pfizer as Executive Vice President and General Counsel and, prior to his appointment as CEO in July 2006, he served as a Vice Chairman of the Company. In 1996, Mr. Kindler joined McDonald’s Corporation as Executive Vice President and General Counsel and in 1990 Mr. Kindler joined the General Electric Company as Vice President of Litigation and Legal Policy.
Mr. Kindler earned his BA in 1977 from Tufts University summa cum laude and his JD in 1980 from Harvard magna cum laude, where he was an editor of the Harvard Law Review.
Stephen L. Holcombe
President, Chief Executive Officer
Mr. Holcombe received his Bachelor of Science degree in accountancy from Wake Forest University. Mr. Holcombe brings over 23 years of financial and managerial experience to vTv Therapeutics. Over that time Mr. Holcombe has primarily been involved as an executive officer with early stage companies focusing on the execution of private and public financings, developing corporate alliance and partnership strategies and managing relationships with external constituents. From 1978 to 1985 he served in various positions of increasing responsibility with KPMG Peat Marwick. From 1985 to 1999 Mr. Holcombe served as Executive Vice President and Chief Financial Officer of Vanguard Cellular Systems, Inc., one of the largest independent wireless operators in the United States, until its sale to AT&T Wireless. Just prior to joining vTv, Mr. Holcombe served as Executive Vice President and Chief Financial Officer for BuildNet, Inc. an e-commerce software solutions provider to the residential construction industry.
Rudy C. Howard, CPA
Executive Vice President, Chief Financial Officer
Mr. Howard brings over 30 years of senior management experience to vTv Therapeutics. Prior to joining the Company, Mr. Howard served as Chief Financial Officer of SciQuest, Inc., an international spend management software company. Before joining SciQuest, he was CFO of MDS Pharma Services, a multi-national pharmaceutical services organization. He has also served as CFO for a number of other public and private multi-national companies in the life sciences and software industries, including Pharmaceutical Product Development (PPD), a global pharmaceutical organization.
Mr. Howard spent the first half of his career in public accounting, where he became an assurance partner with PricewaterhouseCoopers. He served companies in the pharmaceutical, biotechnology, high technology and financial services industries. Among his areas of expertise were public company disclosure compliance, including guiding a number of clients through the IPO process, and merger and acquisition consulting.
Mr. Howard is a certified public accountant and received his B.A. in accounting from North Carolina State University.
Robin E. Abrams, J.D.
Executive Vice President, General Counsel
Robin Abrams joined vTv Therapeutics as Executive Vice President, General Counsel in July, 2016. Ms. Abrams also serves as General Counsel and Chief Administrative Officer at SIGA Technologies Inc.
Prior to joining vTv, Ms. Abrams had a fourteen-year tenure at Purdue Pharma L.P., where she served as Vice President and Associate General Counsel. While at Purdue, Ms. Abrams was Purdue’s primary legal contact with government entities including the Department of Justice, Drug Enforcement Administration and other federal, state and local authorities. Ms. Abrams also served as Purdue’s liaison with congressional committees and caucuses that focused on issues related to Purdue’s products, such as abuse and diversion of opioid pharmaceutical products. Ms. Abrams also oversaw Purdue’s legal regulatory, employment, and government litigation groups.
Prior to Purdue, Ms. Abrams served as an Assistant United States Attorney in the Southern District of New York and prior to that, Ms. Abrams clerked for then-Chief Judge Jack B. Weinstein, federal District Court, Eastern District of New York.
Ms. Abrams earned her Juris Doctor degree from New York University School of Law, and her Bachelor of Arts degree from Cornell University.
Carmen Valcarce, Ph.D.
Executive Vice President, Chief Scientific Officer
Dr. Valcarce obtained her Ph.D. at the Universidad Autonoma de Madrid, Spain in 1988 under the direction of Prof. Jose M. Cuezva in the field of metabolic diseases with focus on mitochondrial development and maturation after birth. From 1989 to 1998 Dr. Valcarce completed her postdoctoral studies and held the position of Assistant Professor at the Department of Clinical Chemistry at Lund University, Sweden under the direction of Prof. Johan Stenflo. During this time, the focus of her research was to understand the structure-function relationship of the various coagulation factors as well the EGF-precursor protein. Dr. Valcarce joined Excorim AB in 1998 to pursue the development of a plasmaphoreis-like system suitable to remove anti-Gal antibodies prior to kidney xeno-transplantation. In 2000, Dr. Valcarce returned to the metabolic disease area and joined Novo Nordisk where she was the project leader of the glucokinase activator project from idea to FHD. Dr. Valcarce is the author of numerous papers and presentations, and is an inventor on several patents and patent applications.
Aaron H. Burstein, PharmD
SVP, Clinical Development
Dr. Aaron Burstein obtained his BS and Pharm.D. degrees from the State University of New York at Buffalo. Dr. Burstein completed his post-doctoral research fellowship at the Dent Neurologic Institute where his training focused on investigational treatments for neurologic disorders, including stroke and epilepsy, as well as on pharmacokinetic/pharmacodynamic data analysis techniques.
He subsequently held an Assistant Professor appointment at the University of Maryland School of Pharmacy prior to joining the National Institute of Health’s Clinical Pharmacokinetics Research Laboratory where he collaborated with NINDS investigator on PK/PD analysis as well as maintained an independent research program focused on the evaluation of herb-drug interactions.
Prior to his current position at vTv Therapeutics, Dr. Burstein was Senior Director at Pfizer where he held various positions of increasing responsibility within Clinical and Developmental Operations organizations, with a focus on investigational products for CNS indications including Alzheimer’s disease.
Dr. Burstein is a Fellow of the American College of Clinical Pharmacy. He has 18 years experience in the pharmaceutical industry and has authored numerous original articles and scientific abstracts over his career in academia, government and industry.
Robert C. Andrews, Ph.D.
SVP Chemistry, Pharmaceutical Development and Quality
Dr. Andrews obtained his Ph.D. at the University of South Carolina in 1986 under the direction of Prof. James Marshall and completed postdoctoral studies in 1988 with Prof. Albert Meyers at Colorado State University. Dr. Andrews joined Glaxo Research and Development in 1988, pursuing orally active phospholipase A2 inhibitors and therapeutic agents for benign prostatic hyperplasia (BPH). With Glaxo Wellcome Dr. Andrews progressed to the area of proteases and his team discovered potent inhibitors of tumor necrosis factor – alpha convertase (TACE) possessing oral activity in animal models of inflammatory disease. Dr. Andrews is the author of numerous papers and presentations, and is an inventor on numerous patents and patent applications.
Imogene Dunn, Ph.D.
SVP, BioMetrics and Regulatory
Imogene Dunn, Ph.D., has more than 25 years of experience in data science services (including data management, biostatistics, and applications of information technology to the clinical development process) and also in regulatory affairs. A key focus of her career has been regulatory data sciences, leveraging progressive methodologies compliant with regulatory expectations while assuring integrated analyses and data files are suitable for registration packages.
Prior to joining vTv Therapeutics, Dr. Dunn served as Vice President of Data Sciences Strategic Services at PAREXEL; Vice President, Statistics, Data Management and Informatics at Regeneron Pharmaceuticals, where she provided statistical and data management expertise for all phases of drug development research. Previously, she was Vice President Statistics and Data Management at Yamanouchi Pharma America, now Astellas Pharma, Infinity, and CATO Research, and she held senior management positions at Pfizer and GlaxoSmithKline.
Dr. Dunn holds a Ph.D. in Biostatistics from the University of North Carolina at Chapel Hill, and Master’s and Bachelor’s degrees in mathematics from the University of North Carolina at Greensboro. A focus of Dr. Dunn’s career has been regulatory submissions of marketing applications using electronic media and in particular ensuring an understanding of regulatory expectations for statistics and data management. She currently serves as a Board Member of the Data Quality Research Institute, and is a member of industry organizations. Dr. Dunn has presented several training courses and has authored numerous articles on data management and statistics topics.
Samuel B. Rollins, Ph.D.,J.D.
SVP, Intellectual Property
Dr. Rollins earned a Bachelor of Science degree in Chemistry from the University of North Carolina at Chapel Hill and a Ph.D. in Chemistry from Colorado State University under the direction of Prof. Robert M. Williams. His doctoral thesis was directed to the design and stereocontrolled synthesis of an eight-membered ring precursor to a photo-triggered mitosene. Following graduate school, Dr. Rollins earned a Juris Doctorate from Wake Forest University School of Law and practiced patent law at Kilpatrick Stockton LLP. While practicing at Kilpatrick Stockton, Dr. Rollins worked with clients in all aspects of patent prosecution, with an emphasis on chemistry, particularly pharmaceutical products and targets, as well as other small molecules (e.g., dyes, probes and binding agents). Dr. Rollins also worked in the strategic development of patent portfolios and provided due diligence reviews of targeted companies and technology.